STAMFORD, Conn. --(BUSINESS WIRE)--Dec. 16, 2024-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the 43rd Annual J.P. Morgan Healthcare Conference from January 12-16 in San Francisco, CA.
STAMFORD, Conn. --(BUSINESS WIRE)--Dec. 5, 2024-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Biogen (Nasdaq: BIIB), Praxis Precision Medicines (Nasdaq: PRAX ) and Stoke Therapeutics (Nasdaq: STOK) as the founding partners to its
STAMFORD, Conn. --(BUSINESS WIRE)--Nov. 22, 2024-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the Piper Sandler 36th Annual Healthcare Conference from December 3-5 in New York City , NY.
New Biopharma Solution Aims to Accelerate the Delivery of Precision Medicine to More Patients STAMFORD, Conn. --(BUSINESS WIRE)--Nov. 19, 2024-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced GeneDx Discover, a first-of-its-kind data
Veteran Legal Executive from Zoetis and Pfizer Joins GeneDx Executive Leadership Team to Lead Legal, Compliance and Policy Functions STAMFORD, Conn. --(BUSINESS WIRE)--Nov. 18, 2024-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the
Data demonstrates the strength of GeneDx’s diverse database; exome diagnostic rate is high regardless of patient’s ancestral background GeneDx industry leading dataset from 46% non-white populations STAMFORD, Conn. --(BUSINESS WIRE)--Nov. 7, 2024-- GeneDx (Nasdaq: WGS), a leader in delivering
Data to be presented showcasing GeneDx’s ongoing commitment to spearheading industry-leading research to drive transformational clinical utility STAMFORD, Conn. --(BUSINESS WIRE)--Nov. 4, 2024-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today
Achieved profitability milestone with third quarter adjusted net income 1 of $1.2M Reported third quarter 2024 revenues 2 of $76.6M with 77% year-over-year growth of exome and genome test revenue Expanded third quarter 2024 adjusted gross margins 2 to 64% Raising guidance to deliver between $284M
Findings published today in JAMA ( Journal of the American Medical Association ) reveal limitations of current screening methods and showcase the promise of advanced genomic technology to deliver equitable health care for all children STAMFORD, Conn. --(BUSINESS WIRE)--Oct.
Data to be presented at the International Conference on Newborn Sequencing (ICoNS) highlighting lessons learned from the GUARDIAN and Early Check newborn sequencing studies showcasing GeneDx’s deep expertise as the leader for gNBS STAMFORD, Conn. --(BUSINESS WIRE)--Oct.